Skip to main content

Advertisement

SpringerLink
Log in

Novel therapies in peripheral T-cell lymphomas

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of disorders associated with a very poor prognosis. Historically, treatment protocols have been largely based on regimens used to treat aggressive B-cell lymphomas; unfortunately, the efficacy of these regimens has been suboptimal, with most patients experiencing relapse after initial therapy. An improved understanding of the molecular biology, pathogenesis, and progression of these disorders has led to the development of a variety of novel targeted agents that may improve outcomes in patients with PTCLs. The purpose of this review is to focus on these novel agents and the various treatment approaches that are currently being evaluated in PTCLs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jaffe ES, Harris NL, Stein H, et al.: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.

    Google Scholar 

  2. Fisher RI, Gaynor ER, Dahlberg S, et al.: A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate-or high-grade non-Hodgkin’s lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 1994, 5(Suppl 2):91–95.

    PubMed  Google Scholar 

  3. Gallamini A, Stelitano C, Calvi R, et al.: Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004, 103:2474–2479.

    Article  PubMed  CAS  Google Scholar 

  4. Savage KJ, Chhanabhai M, Gascoyne RD, et al.: Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004, 15:1467–1475.

    Article  PubMed  CAS  Google Scholar 

  5. Lopez-Guillermo A, Cid J, Salar A, et al.: Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 1998, 9:849–855.

    Article  PubMed  CAS  Google Scholar 

  6. Sallah S, Wan JY, Nguyen NP: Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001, 113:185–187.

    Article  PubMed  CAS  Google Scholar 

  7. Rudiger T, Weisenburger DD, Anderson JR, et al.: Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 2002, 13:140–149.

    Article  PubMed  CAS  Google Scholar 

  8. Gisselbrecht C, Gaulard P, Lepage E, et al.: Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 1998, 92:76–82.

    PubMed  CAS  Google Scholar 

  9. Vose JM: The International PTCL Project. International Peripheral T-Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: poor outcome by prognostic indices and lack of efficacy with anthracyclines [abstract]. Blood 2005, 106:811a.

    Google Scholar 

  10. Armitage JO, Vose JM, Weisenburger DD: Towards understanding the peripheral T-cell lymphomas. Ann Oncol 2004, 15:1447–1449.

    Article  PubMed  CAS  Google Scholar 

  11. Savage KJ: Peripheral T-cell lymphomas. Blood Rev 2007, 21:201–216.

    Article  PubMed  CAS  Google Scholar 

  12. Corradini P, Dodero A, Zallio F, et al.: Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004, 22:2172–2176.

    Article  PubMed  Google Scholar 

  13. Gianni L: Anthracycline resistance: the problem and its current definition. Semin Oncol 1997, 24:S10-11–S10-17.

    Google Scholar 

  14. Zinzani PL, Magagnoli M, Bendandi M, et al.: Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 1998, 9:1351–1353.

    Article  PubMed  CAS  Google Scholar 

  15. Moufarij MA, Phillips DR, Cullinane C: Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol Pharmacol 2003, 63:862–869.

    Article  PubMed  CAS  Google Scholar 

  16. Peters GJ, Bergman AM, Ruiz van Haperen VW, et al.: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995, 22:72–79.

    PubMed  CAS  Google Scholar 

  17. Bergman AM, Ruiz van Haperen VW, Veerman G, et al.: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996, 2:521–530.

    PubMed  CAS  Google Scholar 

  18. Baetz T, Belch A, Couban S, et al.: Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003, 14:1762–1767.

    Article  PubMed  CAS  Google Scholar 

  19. Spencer A, Reed K, Arthur C: Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Intern Med J 2007, 37:760–766.

    PubMed  CAS  Google Scholar 

  20. Emmanouilides C, Colovos C, Pinter-Brown L, et al.: Pilot study of fixed-infusion rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refratory lymphoma. Clin Lymphoma 2004, 5:45–49.

    Article  PubMed  CAS  Google Scholar 

  21. Arkenau HT, Chong G, Cunningham D, et al.: Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 2007, 92:271–272.

    Article  PubMed  CAS  Google Scholar 

  22. Kim JG, Sohn SK, Chae YS, et al.: CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 2006, 58:35–39.

    Article  PubMed  CAS  Google Scholar 

  23. Wang ES, O’Connor O, She Y, et al.: Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003, 44:1027–1035.

    Article  PubMed  CAS  Google Scholar 

  24. Schmid FA, Sirotnak FM, Otter GM, et al.: New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice. Cancer Treat Rep 1985, 69:551–553.

    PubMed  CAS  Google Scholar 

  25. Sirotnak FM, DeGraw JI, Schmid FA, et al.: New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemother Pharmacol 1984, 12:26–30.

    PubMed  CAS  Google Scholar 

  26. O’Connor OA: Pralatrexate: an emerging new agent with activity in T-cell lymphomas. Curr Opin Oncol 2006, 18:591–597.

    Article  PubMed  CAS  Google Scholar 

  27. O’Connor OA, Hamlin PA, Portlock C, et al.: Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 2007, 139:425–428.

    Article  PubMed  CAS  Google Scholar 

  28. O’Connor OA, Hamlin PA, Gerecitano J, et al.: Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-cell lymphomas: results of the MSKCC phase I/II experience [abstract]. Blood 2006, 108:400a.

    Article  Google Scholar 

  29. Toner LE, Vrhovac R, Smith EA, et al.: The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin’s lymphoma. Clin Cancer Res 2006, 12:924–932.

    Article  PubMed  CAS  Google Scholar 

  30. Enblad G, Hagberg H, Erlanson M, et al.: A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2003, 103:2920–2924.

    Article  PubMed  CAS  Google Scholar 

  31. Rodig SJ, Abramson JS, Pinkus GS, et al.: Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006, 12:7174–7179.

    Article  PubMed  CAS  Google Scholar 

  32. Piccaluga PP, Agostinelli C, Righi S, et al.: Expression of CD52 in peripheral T-cell lymphoma. Haematologica 2007, 92:566–567.

    Article  PubMed  Google Scholar 

  33. Went P, Agostinelli C, Gallamini A, et al.: Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006, 24:2472–2479.

    Article  PubMed  CAS  Google Scholar 

  34. Kim JG, Sohn SK, Chae YS, et al.: Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007, 60:129–134.

    Article  PubMed  CAS  Google Scholar 

  35. Gallamini A, Zaja F, Patti C, et al.: Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007, 110:2316–2323.

    Article  PubMed  CAS  Google Scholar 

  36. Ansell SM, Horwitz SM, Engert A, et al.: Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007, 25:2764–2769.

    Article  PubMed  CAS  Google Scholar 

  37. Forero-Torres A, Bernstein S, Gopal A, et al.: SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma [abstract]. Blood 2004, 104:2637a.

    Article  CAS  Google Scholar 

  38. D’Amore F, Radford J, Jerkeman M, et al.: Zanolimumab (HuMax-CD4TM), a fully human monoclonal antibody: efficacy and safety in patients with relapsed or treatment-refractory non-cutaneous CD4+ T-cell lymphoma [abstract]. Blood 2007, 110:3409a.

    Google Scholar 

  39. Foss FM: DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin Lymphoma 2000, 1:110–116; discussion 117.

    Article  PubMed  CAS  Google Scholar 

  40. Dang NH, Pro B, Hagemeister FB, et al.: Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007, 136:439–447.

    Article  PubMed  CAS  Google Scholar 

  41. Ruddle JB, Harper CA, Honemann D, et al.: A denileukin diftitox (Ontak) associated retinopathy? Br J Ophthalmol 2006, 90:1070–1071.

    Article  PubMed  CAS  Google Scholar 

  42. Foss FM, Sjak-Shie N, Goy A, et al.: A Phase II study of denileukin diftitox (Ontak) with CHOP chemotherapy in patients with newly-diagnosed aggressive T-cell lymphomas, the CONCEPT trial: interim analysis [abstract]. Blood 2006, 108:2461a.

    Google Scholar 

  43. Ueda H, Manda T, Matsumoto S, et al.: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobac-terium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 1994, 47:315–323.

    CAS  Google Scholar 

  44. Ueda H, Nakajima H, Hori Y, et al.: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobac-terium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994, 47:301–310.

    CAS  Google Scholar 

  45. Ueda H, Nakajima H, Hori Y, et al.: Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem 1994, 58:1579–1583.

    Article  PubMed  CAS  Google Scholar 

  46. Lee JS, Paull K, Alvarez M, et al.: Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 1994, 46:627–638.

    PubMed  CAS  Google Scholar 

  47. Piekarz RL, Robey R, Sandor V, et al.: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001, 98:2865–2868.

    Article  PubMed  CAS  Google Scholar 

  48. Piekarz R, Frye R, Wright J, et al.: Update of the NCI multi-institutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma [ASCO abstract]. J Clin Oncol 2007, 25:8027.

    Google Scholar 

  49. Sandor V, Bakke S, Robey RW, et al.: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002, 8:718–728.

    PubMed  CAS  Google Scholar 

  50. Piekarz RL, Frye AR, Wright JJ, et al.: Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006, 12:3762–3773.

    Article  PubMed  CAS  Google Scholar 

  51. Reiman T, Finch D, Chua N, et al.: First report of a phase II clinical trial of lenalidomide oral therapy for peripheral T-cell lymphoma [abstract]. Blood 2007, 110:2579a.

    Article  CAS  Google Scholar 

  52. Zinzani PL, Alinari L, Tani M, et al.: Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 2005, 90:702–703.

    PubMed  CAS  Google Scholar 

  53. Moon J, Kim J, Sohn S, et al.: Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas [ASCO abstract]. J Clin Oncol 2007, 25:8069a.

    Google Scholar 

  54. Weidmann E, Hess G, Krause SW, et al.: Combination chemoimmunotherapy using alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) is an effective first-line regimen in peripheral T-cell lymphomas [abstract]. Blood 2004, 104:2640a.

    Google Scholar 

  55. Trumper LH, Hohloch K, Kloess M, et al.: CHOP/CHOEP-14 followed by consolidation with alemtuzumab in untreated aggressive T-cell lymphomas (DSHNHL 2003-1): feasibility and toxicity of a phase II trial of the German High Grade Non-Hodgkin’s Lymphoma Group DSHNHL [ASCO abstract]. J Clin Oncol 2006, 24(18S):7538.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada

    Kerry J. Savage

Authors
  1. Hilary M. O’Leary
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kerry J. Savage
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kerry J. Savage.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O’Leary, H.M., Savage, K.J. Novel therapies in peripheral T-cell lymphomas. Curr Hematol Malig Rep 3, 213–220 (2008). https://doi.org/10.1007/s11899-008-0030-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-008-0030-x

Keywords

Search

Navigation